OBJECTIVES: This study sought to evaluate differential effects of @entity1386 ( @entity1386 ) and subcutaneous fat and their effects on @entity209 ( @entity209 ) risk across body mass index (BMI) categories. BACKGROUND: The regional distribution of adipose tissue is an emerging risk factor for @entity66 , although serial changes in fat distribution have not been extensively investigated. @entity1386 and its alterations over time may be a better marker for risk than BMI in normal weight and overweight or @entity28 individuals. METHODS: We studied 1,511 individuals in the MESA (Multi-Ethnic Study of @entity731 ) with adiposity assessment by computed tomography (CT). A total of 253 @entity1 without @entity209 at initial scan underwent repeat CT (median interval 3.3 years). We used discrete Cox regression with net reclassification to investigate whether baseline and changes in @entity1386 area are associated with @entity209 . RESULTS: Higher @entity1386 was associated with cardiometabolic risk and @entity729 , regardless of BMI. After adjustment, @entity1386 was more strongly associated with incident @entity209 than subcutaneous fat regardless of weight, with a 28% greater @entity209 hazard per 100 cm(2)/m @entity1386 area and significant net reclassification (net reclassification index: 0.44, 95% confidence interval [CI]: 0.29 to 0.60) over clinical risk. In individuals with serial imaging, initial @entity1386 (hazard ratio: 1.24 per 100 cm(2)/m, 95% CI: 1.08 to 1.44 per 100 cm(2)/m, p  = 0.003) and change in @entity1386 (hazard ratio: 1.05 per 5% change, 95% CI: 1.01 to 1.08 per 5% change, p  = 0.02) were associated with @entity209 after adjustment. Changes in subcutaneous fat were not associated with incident @entity209 after adjustment for clinical risk and @entity1386 area. CONCLUSIONS: @entity1386 is modestly associated with BMI. However, across BMI, a single measure of and longitudinal change in @entity1386 predict @entity209 , even accounting for weight changes. Visceral adiposity is essential to assessing cardiometabolic risk, regardless of age, race, or BMI, and may serve as a marker and target of therapy in @entity66 .

Visceral Adiposity and the Risk of XXXX Across Body  Mass  Index: The MESA Study.

@entity1 :: ('9606', 'Species') :: ['participants'] @entity66 :: ('MESH:D004194', 'Disease') :: ['cardiometabolic disease'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obese'] @entity729 :: ('MESH:D061205', 'Disease') :: ['coronary artery calcification'] @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic syndrome', 'MetS'] @entity731 :: ('MESH:D050197', 'Disease') :: ['Atherosclerosis'] @entity1386 :: ('MESH:D018205', 'Disease') :: ['visceral fat', 'VF']
@entity209 :: (MESH:D008659,Disease) :: ['Metabolic Syndrome']
